A	a	O	O	O	O
prospective	prospective	O	O	O	O
study	study	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
dose	dose	O	O	O	O
dependency	dependency	O	O	O	O
of	of	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
mitomycin	mitomycin	O	O	O	O
C.Since	c.since	O	O	O	O
1975	1975	O	O	O	O
mitomycin	mitomycin	O	O	OTHERS	I
C	c	O	O	OTHERS	I
(	(	O	O	O	O
MMC	mmc	O	O	OTHERS	I
)	)	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
suggested	suggested	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
cardiotoxic	cardiotoxic	O	DISEASE	OTHERS	I
,	,	O	O	O	O
especially	especially	O	O	O	O
when	when	O	O	O	O
combined	combined	O	O	O	O
with	with	O	O	O	O
or	or	O	O	O	O
given	given	O	O	O	O
following	following	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Data	data	O	O	O	O
on	on	O	O	O	O
dose	dose	O	O	O	O
dependency	dependency	O	O	O	O
or	or	O	O	O	O
incidence	incidence	O	O	O	O
concerning	concerning	O	O	O	O
this	this	O	O	O	O
side	side	O	O	O	O
effect	effect	O	O	O	O
were	were	O	O	O	O
not	not	O	O	O	O
known	known	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
have	have	O	O	O	O
initiated	initiated	O	O	O	O
a	a	O	O	O	O
prospective	prospective	O	O	O	O
study	study	O	O	O	O
to	to	O	O	O	O
obtain	obtain	O	O	O	O
some	some	O	O	O	O
more	more	O	O	O	O
data	data	O	O	O	O
on	on	O	O	O	O
these	these	O	O	O	O
subjects	subjects	O	O	O	O
.	.	O	O	O	O

Forty-four	forty-four	O	O	O	O
MMC-treated	mmc-treated	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
studied	studied	O	O	O	O
,	,	O	O	O	O
37	37	O	O	O	O
of	of	O	O	O	O
them	them	O	O	O	O
could	could	O	O	O	O
be	be	O	O	O	O
evaluated	evaluated	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
studied	studied	O	O	O	O
by	by	O	O	O	O
repeated	repeated	O	O	O	O
physical	physical	O	O	O	O
examinations	examinations	O	O	O	O
,	,	O	O	O	O
chest	chest	O	O	O	O
X-rays	x-rays	O	O	O	O
,	,	O	O	O	O
electro-	electro-	O	O	O	O
and	and	O	O	O	O
echocardiography	echocardiography	O	O	O	O
and	and	O	O	O	O
radionuclide	radionuclide	O	O	O	O
left	left	O	O	O	O
ventricular	ventricular	O	O	O	O
ejection	ejection	O	O	O	O
fraction	fraction	O	O	O	O
(	(	O	O	O	O
EF	ef	O	O	O	O
)	)	O	O	O	O
determinations	determinations	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
results	results	O	O	O	O
were	were	O	O	O	O
evaluated	evaluated	O	O	O	O
per	per	O	O	O	O
cumulative	cumulative	O	O	O	O
dose	dose	O	O	O	O
level	level	O	O	O	O
.	.	O	O	O	O

One	one	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
developed	developed	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
after	after	O	O	O	O
30	30	O	O	O	O
mg	mg	O	O	OTHERS	I
m-2	m-2	O	O	O	O
MMC	mmc	O	O	OTHERS	I
and	and	O	O	O	O
only	only	O	O	O	O
150	150	O	O	O	O
mg	mg	O	O	OTHERS	I
m-2	m-2	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
cardiac	cardiac	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
was	was	O	O	O	O
predicted	predicted	O	O	O	O
by	by	O	O	O	O
a	a	O	O	O	O
drop	drop	O	O	O	O
in	in	O	O	O	O
EF	ef	O	O	O	O
determined	determined	O	O	O	O
during	during	O	O	O	O
a	a	O	O	O	O
cold	cold	O	O	O	O
pressor	pressor	O	O	O	O
test	test	O	O	O	O
.	.	O	O	O	O

None	none	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
other	other	O	O	O	O
patients	patients	O	O	O	O
developed	developed	O	O	O	O
clinical	clinical	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
,	,	O	O	O	O
nor	nor	O	O	O	O
did	did	O	O	O	O
the	the	O	O	O	O
studied	studied	O	O	O	O
parameters	parameters	O	O	O	O
change	change	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
literature	literature	O	O	O	O
on	on	O	O	O	O
this	this	O	O	O	O
subject	subject	O	O	O	O
was	was	O	O	O	O
also	also	O	O	O	O
reviewed	reviewed	O	O	O	O
.	.	O	O	O	O

Based	based	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
combined	combined	O	O	O	O
data	data	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
present	present	O	O	O	O
study	study	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
literature	literature	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
MMC-related	mmc-related	O	O	O	O
cardiotoxicity	cardiotoxicity	O	DISEASE	OTHERS	I
is	is	O	O	O	O
dose	dose	O	O	O	O
dependent	dependent	O	O	O	O
,	,	O	O	O	O
occurring	occurring	O	O	O	O
at	at	O	O	O	O
cumulative	cumulative	O	O	O	O
dose	dose	O	O	O	O
levels	levels	O	O	O	O
of	of	O	O	O	O
30	30	O	O	O	O
mg	mg	O	O	OTHERS	I
m-2	m-2	O	O	O	O
or	or	O	O	O	O
more	more	O	O	O	O
,	,	O	O	O	O
mainly	mainly	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
also	also	O	O	O	O
(	(	O	O	O	O
previously	previously	O	O	O	O
or	or	O	O	O	O
simultaneously	simultaneously	O	O	O	O
)	)	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
doxorubicin	doxorubicin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
incidence	incidence	O	O	O	O
is	is	O	O	O	O
likely	likely	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
less	less	O	O	O	O
than	than	O	O	O	O
10	10	O	O	O	O
%	%	O	O	O	O
even	even	O	O	O	O
for	for	O	O	O	O
this	this	O	O	O	O
risk	risk	O	O	O	O
group	group	O	O	O	O
.	.	O	O	O	O

